Use of metformin does not appear to improve survival rates among older women with incident diabetes and breast cancer, according to a new study. Using administrative health care databases in Ontario, Canada, researchers conducted a population-based study of 2,361 women aged >=66 years with recent-onset diabetes who received a breast cancer diagnosis between April 1, 1997, and March 31, 2008. The women were followed through death or March 30, 2010, whichever came first. Mean follow-up was...
Use of metformin does not appear to improve survival rates among older women with incident diabetes and breast cancer, according to a new study.
Using administrative health care databases in Ontario, Canada, researchers conducted a population-based study of 2,361 women aged >=66 years with recent-onset diabetes who received a breast cancer diagnosis between April 1, 1997, and March 31, 2008. The women were followed through death or March 30, 2010, whichever came first. Mean follow-up was 4.5 years.
The primary outcome was all-cause mortality, and the secondary outcome was breast-cancer specific mortality.
In total, there were 1,101 (46.6%) deaths during follow-up, including 386 (15.1%) breast cancer-specific deaths.
Despite previous studies linking metformin use with a reduction in breast cancer risk and breast cancer survival, the current study showed no statistically significant association between cumulative duration of past metformin use and all-cause or breast cancer-specific survival (hazard ratio [HR], 0.97; 95% CI, 0.92-1.02 and HR, 0.91; 95% CI, 0.81-1.03, respectively).
However, the authors noted, the "possible 9% decrease in breast cancer-specific mortality per additional year of cumulative metformin use" translates into a potential 38% decrease over 5 years.
There was a significant increase in breast-cancer specific deaths per additional year of exposure to thiazolidinediones (HR, 1.52; 95% CI, 1.02-2.26) and a significant reduction in all-cause mortality per additional year of sulfonylurea exposure (HR, 0.95; 95% CI, 0.89-0.99).
Because of the small number of women with long-term metformin exposure and the short follow-up for breast cancer-specific mortality (3.7 years), the researchers said the study might have lacked the power to detect a statistically significant outcome.
"Further work is required to examine the effect of metformin in a younger population of patients with breast cancer and diabetes as well as in a prevalent diabetic population, although careful attention will be needed to minimize indication bias in such a cohort and in nondiabetic populations," they wrote.
"A better understanding of metformin's effect on breast cancer is essential to help address the disparity in cancer outcomes between patients with and without diabetes, as well as to guide diabetes treatment strategies in this population."
The study results were published online April 30 ahead of print in the journal Diabetes Care by Lega I, et al.
After receiving clearance from the Food and Drug Administration, Shanghai-based Generon Corp. Ltd. started a Phase II study of F-627 in women with breast cancer who are receiving myelotoxic chemotherapy.
Approximately 200 patients will be included in the randomized, open-label trial. The main objective is to evaluate the efficacy and safety of various once-per-cycle dosing of F-627 as...
The addition of Genentech Inc.'s Avastin (bevacizumab) to a chemotherapy regimen consisting of gemcitabine hydrochloride and carboplatin leads to improvements in progression-free survival (PFS) for patients with platinum-sensitive recurrent ovarian, primary peritoneal or fallopian tube cancers, according to data from the Phase III OCEANS trial.
Additional data from the trial suggested that Avastin was also associated with improvements in...
Genentech Inc. and Dako A/S agreed to collaborate on the U.S. regulatory submissions for Dako's HercepTest and HER2 (human epidermal growth factor receptor 2) FISH (fluorescence in situ hybridization) pharmDx kit as companion diagnostics for Genentech's investigational compound trastuzumab emtansine.
The regulatory submissions will seek Food and Drug Administration...
Roche reported top-line results from the first randomized Phase III study of trastuzumab emtansine, and based on the findings, the company plans to submit regulatory applications in the United States and Europe this year.
The open-label trial, EMILIA, involved 991 patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer whose disease progressed after initial...